Literature DB >> 6264059

Pubertal development in children treated for nephroblastoma.

J E Scott.   

Abstract

Recent improvements in the treatment of children with nephroblastoma have led to an increase in the disease-free survival rate. The late effect of treatment on long-term survivors requires assessment to determine whether avoidable iatrogenic disorders are appearing. The onset of puberty is one measurement of physical development and has been used in the study to assess the progress of 16 children over the age of 12 yr who were treated for nephroblastoma. The method consisted of the measuring body height, weight and testicular size, estimating serum levels of luteinizing hormone, follicular stimulating hormone and testosterone, recording the age at menarche, and staging of pubic hair and breast development. There was evidence of complete ovarian suppression in 3 out of 10 girls and of delayed and testicular function in 1 out of 6 boys. Analysis of the treatment received by the children implicated radiotherapy as the responsible factor causing gonadal suppression.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6264059     DOI: 10.1016/s0022-3468(81)80336-3

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

Review 1.  Damage to the urinary tract secondary to irradiation.

Authors:  J Fichtner; R Hohenfellner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

2.  Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Daniel M Green; Toana Kawashima; Marilyn Stovall; Wendy Leisenring; Charles A Sklar; Ann C Mertens; Sarah S Donaldson; Julianne Byrne; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

3.  Factors affecting myocardial infarction in cervical cancer patients: a population-based study.

Authors:  Chen-Hsi Hsieh; Wen-Yen Chiou; Ching-Chih Lee; Moon-Sing Lee; Hon-Yi Lin; Yu-Chieh Su; Shih-Kai Hung
Journal:  J Clin Med Res       Date:  2013-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.